Beneficial actions of polyunsaturated fatty acids in cardiovascular diseases: But, how and why?

Current Nutrition and Food Science

Volumn 4, Issue 1, 2008, Pages 2-31

  Das, Undurti N ^a  

^a UND LIFE SCIENCES   (United States)

Author keywords

Arachidonic acid; Atherosclerosis; Coronary heart disease; Docosahexaenoic acid; Eicosapentaenoic acid; Endothelial cells; Leukocytes; Leukotrienes; Linoleic acid; Lipoxins; Platelets; Polyunsaturated fatty acids; Prostaglandins; Resolvins

Indexed keywords

ALKENE DERIVATIVE; ARACHIDONIC ACID; CHOLESTEROL; CYCLIC AMP; CYTOKINE; DIHOMO GAMMA LINOLENIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE; DOCOSAHEXAENOIC ACID; FATTY ACID; FREE RADICAL; GAMMA LINOLENIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; ICOSANOID; ICOSAPENTAENOIC ACID; INTEGRIN; LIPID; LIPOXIN; NITRIC OXIDE; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN E1; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TELOMERASE; TRIACYLGLYCEROL;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BREAD; CARDIOVASCULAR DISEASE; CEREAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGRANULATION; DIET SUPPLEMENTATION; DYSLIPIDEMIA; EGG; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; FISH; FOOD COMPOSITION; HEART ARRHYTHMIA; HEART DEATH; HEART MUSCLE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; NEUTROPHIL; POULTRY; PRIORITY JOURNAL; PROGNOSIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION; WOUND HEALING;

EID: 39349097862     PISSN: 15734013     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340108783497418     Document Type: Review

References (401)

1. Das UN. Essential fatty acids: Biochemistry, physiology and pathology. Biotech J 2006; 1: 420-439.
2. Das UN. Essential fatty acid metabolism in patients with essential hypertension, diabetes mellitus and coronary heart disease. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 387-391.
3. Das UN. Biological significance of essential fatty acids. J Assoc Physicians India 2007; 54: 309-319.
4. Das UN. Nutritional factors in the pathobiology of human essential hypertension. Nutrition 2001; 17: 337-346.
5. Das UN. Can perinatal supplementation of long chain polyunsaturated fatty acids prevent hypertension in adult life? Hypertension 2001; 38: e6-e8.
6. Das UN. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent diabetes mellitus? Eur J Clin Nutr 2003; 57: 218-226.
7. 5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukotrienes Essen Fatty Acids 2005; 72: 343-350.
8. Wang L, Folsom AR, Eckfeldt JH. Plasma fatty acid composition and incidence of coronary heart disease in middle aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Nutr Metab Cardiovasc Dis 2003; 13: 256-66.
9. Zheng ZJ, Folsom AR, Ma J, Arnett DK, McGovern PG, Eckfeldt JH. Plasma fatty acid composition and 6-year incidence of hypertensionin middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1999; 150: 492-500.
10. Suresh Y, Das UN. Differential effect of saturated, monounsaturated, and polyunsaturated fatty acids on alloxan-induced diabetes mellitus. Prostaglandins Leukot Essen Fatty Acids 2006; 74: 199-213.
11. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-6 fatty acids. Nutrition 2003; 19: 93-114.
12. Suresh Y, Das UN. Long-chain polyunsaturated fatty acids and chemically-induced diabetes mellitus: Effect of ω-3 fatty acids. Nutrition 2003; 19: 213-228.
13. Mozaffarian D, Ascherio A, Hu FB, et al. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111: 157-164.
14. Das UN. Clinical laboratory tools to diagnose inflammation. Adv Clin Chem 2006; 41: 189-229.
15. Brennan ML, Penn MS, Lente FV, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
16. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004; 109: 837-842.
17. 2 activity is associated with risk of coronary heart disease and ischemic stroke. The Rotterdam study Circulation 2005; 111: 570-575.
18. Brevetti G, Schiano V, Sirico G, Giugliano G, Laurenzano E, Chiariello M. Metabolic syndrome in peripheral arterial disease: relationship with severity of peripheral circulatory insufficiency, inflammatory status, and cardiovascular comorbidity. J Vasc Surg 2006; 44: 101-107.
19. Elkind MS, Tai W, Coates K, Paik MC, Sacco PL. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 2006; 166: 2073-2080.
20. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markets and EL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vase Med 2005; 10: 191-198.
21. Nylaende M, Kroese A, Stranden X, et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21-28.
22. Loffredo L, Pignatelli P, Cangemi R, et al. Imbalance between nitric oxide generation and - oxidative stress in patients with peripheral arterial disease: effect of an antioxidant treatment. J Vasc Surg 2006; 44:525-530.
23. Aygul R, Kotan D, Demirbas F, Ulvi H, Deniz O. Plasma oxidants and antioxidants in acute ischaemic stroke. J Int Med Res 2006; 34: 413-418.
24. Collino M, Aragno M, Mastrocola R, et al. Modulation of the oxidative stress and in inflammatory response by PrAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2906; 530: 70-80.
25. Kumar KV, Das UN. Lipid peroxides and essential fatty acids in patients with coronary heart disease. J Nutr Med 1994; 4: 33-37.
26. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure ahd Myocardial infarction. Mol Cell Biochem 2000; 215: 145-152.
27. Lucas AR, Korol R; Pepine Ck Inflammation in atherosclerosis some thoughts about acute coronary syndromes. Circulation 2006; 113: e728-e732.
28. Chambers JC, Chambers JC, Eda S, et al. C-reactive protein, insulin, resistance, central obesity, about acute coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 104: 145-150.
29. Morrow DA, Morrow DA, Rifai N, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460-1465.
30. James SK, Armstrong P, Barnathan E, et al. GUSTO IV ACS investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41: 916-924.
31. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2001; 108: 512-515.
32. Biasucci LM, Liuzzo G, Colizzi C, Rizzello V. Clinical use of C-reactive protem for the prognostic stratification of patients with ischemic heart disease. Ital Heart 2001; 2: 164-171.
33. Ferreiros ER, Boissonnet CP, Pizarro R, Merletti PF, Corrado G, Cagide A, Bazzino OO. Independent prognostic value of C-reactive protein in unstable angina. Circulation 1999; 100: 1958-1963.
34. Benamer H, Steg PG, Benessiano J, et al. Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris, Am J Cardiol 1998; 82: 845-850.
35. Liuzzo G, Liuzzo G, Biasucci LM, et al. The prognostic value of C-reactive protein and semin amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417-424.
36. Heeschen C, Hamm CW, Bruemmer J, Simoons ML. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 Anti-Platelet Therapy in Unstable angina REfractory to standard treatment trial. J Am Coll Cardiol 35: 1535-1542, 2000.
37. Morrow DA, Morrow DA, Rifai N, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998; 31: 1460-146?.
38. Verheggen PW, de Maat MPM, Cats VM, et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur Heart J 1999; 20: 567-574.
39. Mütter C, Buettner HJ, Hodgson JM, et al. Inflammation and longterm mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412-1415.
40. James SK, Armstrong P, Barnathan E, et al. GUSTO IV ACS investigators. Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J Am Coll Cardiol 2003; 41: 916-924.
41. Home BD, Muhlestein JB, Carlquist JF, et al. Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. J Am Coll Cardiol 2000; 36: 1774-1780.
42. Haverkate F, Thompson SG, Pyke SD, Gallimore RJ, Pepys MB. Production of C-reactive protein and the risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349: 462-466.
43. Biasucci LM, Liuzzo G, Grillo RL, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999; 99: 855-860.
44. Bholasingh R, Cornel JH, Kamp O, et al. The prognostic value of markers of inflammation in patients with troponin T-negative chest pain before discharge from the emergency department. Am J Med 2003; 115: 521-528.
45. Toss H, Lindhal B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 4204-4210.
46. Lindhal B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation An relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in coronary Artery Disease. N Engl J Med 2000; 343: 1139-1147.
47. Buffon A, Liuzzo G, Biasucci LM, et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-1521.
48. Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PA. Predictive value of C-reactive protein in patients with unstable angina pectoris undergoing coronary artery stent implantation. Am J Cardiol 2000; 85: 92-95.
49. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-846.
50. Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of C-reactive protein in unstable angina. Circulation 1999; 100: 1958-1963.
51. Wallen NH, Held C, Rehnqvist N, Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction. Eur Heart J 1999; 20:1039-1043.
52. Mulvihill NT, Foley JB, Murphy RT, Curtin R, Crean PA, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-627.
53. Ridker PM, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E. Elevation of tumor necrosis factdr-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153.
54. Patti G, Di Sciascio G, D'Ambrosio A, Dicuonzo G, Abbate A, Dobrina A. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutancous coronary intervention. Am J Cardiol 2002; 89: 372-376.
55. Biasucci LM, Vitelli A, Liuzzo G, et al. Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-877.
56. Biasucci LM, Liuzzo G, Fantuzzi G, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-2084.
57. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 635-641.
58. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: A TIMI 11A substudy. J Am Coll Cardiol 2000; 35: 358-362.
59. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary Heart, disease and cardiovascular outcome in women: the National Heart Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-732.
60. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulaoon 2001; 104: 1598-1603.
61. Maflat Z, Henry P, Fressonnet R, et al. Incresased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88: 467-469.
62. Furchgott RF, Zawadzki JV. The obligatory-role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
63. Nathan C. Inducible nitric oxide synthase: what difference does it make? J Clin Invest 1997; 100: 2417-2423.
64. Das UN. Clinical significance of L-arginine-nitric oxide system. J Assoc Physicians India 1995; 43: 122-126.
65. Laroux FS, Pavlick KP, Hines IN, et al. Role of nitric oxide in inflammation, Acta Physiol Scand 2001; 173: 113.
66. Kumar KV, Das UN. Are free radicais involved ih the pathobiology of human essential hypertension. Free Radic Res Commun 1993. 19: 59-66.
67. Das UN, Krishna Mohah I, Vijay Kumar K, Sravan Kumar G and Chandra Sekhar C. Beneficial effect of L-arginine in non-insulin dependent diabetes mellitus: A potential role for nitric oxide. Med Sci Rep 1993; 21: 669-670.
68. Mohan KI, Das UN. Oxidant stress, anti-oxidants and nitris oxide in non-insulin dependent diabetes mellitus. Med Sci Res 1997; 25: 55-57.
69. Mohan KI, Das UN. Effect of L-arginine-nitric oxide system on chemical induced diabetes mellittis. Free Radic Biol Med 1998; 25: 757-765.
70. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian-hosts and microbial pathogens. Proc-Natl Acad Sci USA 2000; 97: 8841-8847
71. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorpho-nuclear leukocyte. Blood 1997; 89: 3503-3521.
72. Belaaouaj A. Neutrophil elastase-mediated killing of bacteria: lessons from targeted mutagenesis. Microbes Infect 2002; 4: 1259-1264.
73. Borregaard N, Theilgaard-Monch K, Sorensen OE, Cowland JB. Regulation of human neutrophil granule protein expression. Curr Opin Hematol 2001; 8: 23-27,
74. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271: C1424-C1437.
75. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16:42-47.
76. Das UN. Long-chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion, and transforming growth factor-β to prevent human essential hypertension. Eur J Clin Nutr 2004; 58: 195-203.
77. Prescott SM, Zimmerman GA, Stafforini DM, McIntyre TM. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69: 419-445.
78. Tuttle HA, Davis-Gorman G, Goldman S, Copeland JG, McDonagh PF. Platelet-neutrophil conjugate formation is increased in diabetic women with cardiovascular disease. Cardiovasc Diabetol 2003; 2: 12.
79. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phos-pholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in uman and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol 1999; 19: 2909-2917.
80. Chisolm GM, Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 2000; 28: 1815-1826.
81. Macphee CH, Moores, KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338 (Pt 2): 479-487.
82. Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005; 2: 529-535.
83. Sudhir K. Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab 2005; 90: 3100-3105.
84. 2 as an independent predictor of coronary heart disease. N Engl J Med 2000; 343: 1148-1155.
85. 2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities. (ARIC) Study. Circulation 2004; 109: 937-842.
86. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phosoholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26: 1586-1593.
87. 2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem 2006; 52: 1331-1338.
88. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its. association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection. Therapy, Thrombolysis In Myocardial Infarction) trial. Circulation 2006; 113: 1745-1752.
89. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006; 9: 138-143.
90. Folsom AR, Chambless LE, Ballantyne CM, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Interm Med 2006; 166: 1368-1373.
91. Dinerman JL, Mehta JL, Saldeen TG, et al. Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction. J Am Coll Cardiol 1990; 15: 1559-1563.
92. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea E, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med 2002; 347: 5-12.
93. Podrez EA, Schmidt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 1999; 103: 1547-1560.
94. Schmidt D, Shen Z, Zhang R, et al. Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum. Biochemistry 1999; 38: 16904-16915.
95. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science 2002; 296: 2391-2394.
96. Brennan ML, Penn MS, Lente FV, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
97. Ng LL, Pathik B, Loke IW, Squire IB, Davies JE. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Am Heart J 2006; 152: 94-101.
98. X ZM, Zhao, SP, Li QZ, Nie S, Zhou HN. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 2003; 338: 17-24,
99. Zhou T, Zhou SH, Qi SS, Shen X, Zeng GF, Zhou HN. The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acts. 2006; 368: 168-172.
100. Yang J, Li K, Zhao SP, Li J, Li JD, X M. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Clin Chim Acta 2006; 368: 183-187.
101. Luo Y, Jiang D, Wen D, Yang J, Li L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their responses to simvastatin. Heart Vessels 2004; 19: 257-262.
102. Macin SM, Perna ER, Farias EF, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005; 149: 451-457.
103. Deng P, Zhao SP, Dai HY Guan XS, Huang HG. Atorvastatin reduces the expression of CO-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response. Clin Chem 2006; 52: 300-303.
104. Bayorh MA, Ganafa AA, Eatman D, Walton M, Deuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 2005; 18: 1496-1502.
105. Mital S, Zhang X, Zhao G, et al. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000; 279: H2649-H2657.
106. Das UN. Essential fatty acids as possible mediators of the beneficial actions of statins. Prostaglandins Leukot Essent Fatty Acids 2001; 65: 37-40.
107. Levy BD. Myocardial 15-epi-lipoxin A generation provides a new mecha-nism for the immunomodulatory effects of statins and thiazolidinediones. Circulation 2006; 114: 873-875.
108. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-epi-lipoxin A4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929-935.
109. Kumar V, Abbas AK, Fausto N. Acute and chronic inflammation. In Robbins and Cotran Pathologic Basis of Disease, Elsevier Saunders, 7th edition, 2005, pp. 47-86.
110. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 1995; 92: 9475-9479.
111. Cantwell MM, Flynn MA, Cronin D, O'Neill JP, Gibney MJ. Contribution of foods to trans unsaturated fatty acid intake in a group of Irish adults. J Hum Nutr Diet 2005; 18: 377-385.
112. Lopez-Garcia E, Schultze MB, Meig JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 2005; 135: 562-566.
113. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004; 79: 606-612.
114. Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1982; 20: 41-48.
115. Matsuzaka T, Shimano H, Yahagi N, et al. Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha. J Lipid Res 2002; 43: 107-114.
116. Cook HW. The influence of trans acids on desaturation and elongation of fatty acids. Lipids 1981; 16: 920-926.
117. Das UN. COX2 inhibitors and metabolism of essential fatty acids. Med Sci Monit 2005; 11: RA233-RA237.
118. Serhan CN, Clish C B, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 2000; 192: 1197-1204.
119. Serhan CN, Hong S, Gronert K, et al. Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-1037.
120. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation signals in resolution. Nat Immunol 2001; 2: 612-619.
121. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-14687.
122. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-43817.
123. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-8496.
124. Gronert K, Maheshwari N, Khan N, Hasan IR, Dunn M, Laniado-Schwartzman M. A role for the mouse 1215-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005; 280: 15267-15278.
125. Lukiw WJ, Cui J-G, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
126. Calon F, Lim GP, Morihara T, Yang F, Ubeda O, Salem N Jr, Frautschy SA, Cole GM. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimers. Eur J Neurosci 2005; 22: 617-626.
127. Baker PRS, Lin Y, Schopfer FJ, et al. Fatty acid transduction of nitric oxide signaling: Multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem 2005; 280: 42464-42475.
128. Coles B, Bloodsworth A, Clark SR, et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils. Circ Res 2002; 91: 375-381.
129. Lima ES, Bonim MG, Augusto O, Barbeiro HV, Souza HP, Abdalla DSP. Nitrated lipids decompose to nitric oxide and lipid radicals and cause vasorelaxation. Free Radic Biol Med 2005; 39: 532-539.
130. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-1482.
131. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of human aortic endothelial cells exposed to disturbed flow and steady laminar flow. Physiol Genomics 2002; 9: 27-41.
132. Garcia-Cardena G, Comander J, Anderson KR, Blackman BR, Gimbrone MA Jr. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001; 98: 4478-4485.
133. Gimbrone MA Jr, Nagel T, Topper JN. Biomechanical activation: an emerging paradigm in endothelial adhesion biology. J Clin Invest 1997; 100: S61-S65.
134. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-kappa B signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 2000; 97: 9052-9057.
135. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of CAM-1 and ICAM-1 at atheroslcerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol 1998; 18: 842-851.
136. Iiyama K, Hajra L, Iiyama M, et al. Patterns of vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 expression in rabbit and mouse atheroslcerotic lesions and at sites predisposed to lesion formation. Circ Res 1999; 85: 199-207.
137. Passerini AG, Polacek DC, Shi C, et al. Coexisting proinflammatory and antioxidative endothelial transcription profiles in a disturbed flow region of the adult porcine aorta. Proc Natl Acad Sci USA 2004; 101: 2482-2487.
138. Schwenke DC, Carew TE. Initiation of atheroslcerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis 1989; 9: 895-907.
139. Schwenke DC, Carew TE. Initiation of atherosclerotic lesions in cholesterol-fed rabbits. II. Selective retention of LDL vs. selective increases in LDL permeability in susceptible sites of arteries. Arteriosclerosis 1989; 9: 908-918.
140. Schwenke DC. Selective increase in cholesterol at atherosclerosis-susceptible aortic sites after short-term cholesterol feeding. Arterioscler Throm Vasc Biol 1995; 15: 1928-1937.
141. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocytic recruitment into early atherosclerotic lesions. J Clin Invest 1997; 100: 2680-2690.
142. Shi W, Haberland ME, Jien ML, Shih DM, Lusis AJ. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation 2000; 102: 75-81.
143. Cybulsky MI, Won D, Haidari M. Leukocyte recruitment to atherosclerotic lesion. Can J Cardiol 2004; 20 (Suppl. B): 24B-28B.
144. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha, D, Cybulsky MI. Low-grade chronic inflammation in regions of the normal mouse arterial intima predisposed to atherosclerosis. J Exp Med 2006; 203: 2073-2083.
145. Santerre RF, Nicolosi RJ, Smith SC. Respiratory control in preatherosclerotic susceptible and resistant pigeon aortas. Exp Mol Pathol 1974; 20: 397-406.
146. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
147. Nohl H. Generation of superoxide radicals as byproducts of cellular respiration. Ann Biol Clin (Paris) 1994; 52: 199-204.
148. Echtay KS, Roussel D, St-Pierre J, et al. Superoxide activates mitochodrial uncoupling proteins. Nature 2002; 415: 96-99.
149. Murphy MP, Echtay KS, Blaikie FH, et al. Superoxide activates uncoupling proteins by generating carbon-centered radicals and initiating lipid peroxidation: studies using a mitochondria-targeted spin trap derived from alpha-phenyl-N-tert-butylnitrone. J Biol Chem 2003; 278: 48534-48545.
150. Nishikawa T, Edelstein D, Du K, et al. Normalizing mitochondial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-790.
151. Blanc J, Alves-Guerra MC, Esposito B, et al. Protective role of uncoupling protein 2 in atherosclerosis. Circulation 2003; 107: 388-390.
152. Petterson G. Effect of dinitrophenol and anoxia on isometric tension in rabbit colon smooth muscle. Acta Pharmacol Toxicol (Copenh.). 1985; 57: 184-189.
153. Bernal-Mizrachi C, Gates AC, Weng S, et al. Vascular respiratory uncoup-ling increases blood pressure and atherosclerosis. Nature 2006; 435: 502-506.
154. Watts H. In: Evolution of the Atherosclerotic Plaque (ed. Jones RJ) 117, 1963; Univ Chicago, Chicago.
155. Levin M, Leppanen O, Evaldsson M, Wiklund O, Bondjers G, Bjornheden T. Mapping of ATP, glucose, glycogen, and lactate concentrations within the arterial wall. Artesioscler Thromb Vasc Biol 2003; 25: 1801-1807.
156. Jennings RB, Kaltenbach JP, Sommens HM. Mitochondrial metabolism in ischemic injury. Arch Pathol 1967; 84: 15-19.
157. Smith EB. The effects of age and of early atheromata on the intimal lipids in men. Biochem J 1962; 84: 49p.
158. Smith EB. Lipids carried by S1 0-12 lipoprotein in normal and hypercholesterolaemic serum. Lancet 1962; 2: 530-534.
159. Klein PD, Johnson RM. Phosphorous metabolism in unsaturated. fatty acid-deficient rats. J Biol Chem 1954; 211: 103-110.
160. Hayashida T, Portman OW. Swelling of liver mitochondria from rats fed diets deficient in essential fatty acids. Proc Soc Exp Biol Med 1960; 103: 656-659.
161. Cornwell DG, Panganamala RV. Atherosclerosis an intracellular deficiency in essential fatty acids. Prog Lipid Res 1981; 20: 365-376.
162. Das UN. Essential fatty acids- a review. Curr Pharm Biotech 2006; 7: 467-482.
163. Prichard BNC, Smith CGT, Ling KLE, Betteridge DJ. Fish oils and cardiovascular disease. Br Med J 1995; 310: 819-820.
164. Kagawa, Y Nishizawa M, Suzuki M, et al. Eicosapolyenoic acids of serum lipids of Japanese islanders with low incidence of cardiovascular diseases. J Nutr Sci Vitaminol (Tokyo) 1982; 28: 441-453.
165. Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 1985; 312: 1205-1209.
166. Erkkila AT, Lehto S, Pyorala K, Uusitupa MI. n-3 fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr 2003; 78: 65-71.
167. He K, Song, Y Daviglus ML, et al. Accumulated evidence on fish consump-tion and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004; 109: 2705-2711.
168. Dyerberg J, Eskesen DC, Andersen PW, et al. Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males: an 8 weeks dietary intervention study. Eur J Clin Nutr 2004; 58: 1062-1070.
169. Hu FB, Bronner LL, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-1821.
170. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336: 1046-1053.
171. Bucher, HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002; 112: 298-304.
172. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol 2006; 98 (suppl): 3i-18i.
173. Das UN. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how? Prostaglandins Leukot Essent Fatty Acids 2000; 63: 351-362.
174. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diets on mortality: a systemic review. Arch Intern Med 2005; 165: 725-730.
175. GISSI Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
176. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, Part 1, Prolonged differences in blood pressure: prospective observational studies so corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
177. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-838.
178. Goodnight SH, Cairns JA, Fisher M, Fitzerald GA. Assessment of the therapeutic use of n-3 fatty acids, in vascular disease and thrombosis. Chest 1992; 102: 374S-384S.
179. Israel DH, Gorlin R. Fish oils in the prevention of atherosclerosis. J Am Coll Cardiol 1992; 19: 174-185.
180. Albert CM, Hennekens CH, O'Donnel CJ, et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28.
181. Daviglus ML, Stamler J, Orencia AJ, et al. Fish consumption and the 30-year risk of fatal myocardial infarction. N Engl J Med 1997; 336: 1046-1053.
182. Orencia AJ, Daviglus ML, Dyer AR, Shekelle RB, Stamler J. Fish consumption and stroke in men: 30-year findings of the Chicago Western Electric Study. Stroke 1996; 27: 204-209.
183. Dolecek TA, Granditis G. Dietary polyunsaturated fatty acids and mortality in the Multiple Risk Factor Intervention Trial (MRFIT). World Rev Nutr Diet 1991; 66: 205-216.
184. Gillum RF, Mussolino M, Madans JH. The relation between fish consumption, death from all causes, and incidence of coronary heart disease: the NHANES I epidemiologic Follow-up Study. J Clin Epidemiol 2000; 53: 237-244.
185. Jarvinen R, Knekt P, Rissanen H, Reunanen A. Intake of fish and long-chain n-3 fatty acids and the risk of coronary heart mortality in men and women. Br J Nutr 2006; 95: 824-829.
186. Burr ML, Ashfield-Watt PA, Dunstan FD, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003; 57: 193-200.
187. Hu FB, Bronner LL, Willett WC, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002; 287: 1815-1821.
188. Osler M, Andreasen AH, Hoidrup S. No Inverse association between fish consumption and risk of death from all-causes, and incidence of coronary heart disease in middle-aged, Danish adults. J Clin Epidemiol 2003; 56: 274-279.
189. Rodriguez BL, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers: the Honolulu Heart Program. Circulation 1996; 94: 952-956.
190. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE. Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 2003; 107; 1852-1857.
191. Mozaffarian D, Longstreth WT Jr, Lemaitre RN, et al. Fish consumption and stroke risk ih elderly, individuals: the Cardiovascular Health Study. Arch Intern Med 2005; 165: 200-206.
192. Ken SO, Feskens EJ, Kromhout D. Fish consumption and risk of stroke: the Zutphen Study. Stroke 1994; 25: 328-332.
193. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, Goldbourt U, Greenland P. Fish consumption and incidence of stroke: a meta-analysis of cohort studies. Stroke 2004; 35: 1538-1542.
194. Guallar E, Aro A, Jimenez FJ, et al. Omega-3 fatty acids in Adipose-tissue and risk of myocardial infarction: the EURAMIC study. Arterioscler Throm Vasc Biol 1999; 19: 1111-1118.
195. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999; 99: 779-785.
196. Zhang J, Sasaki S, Amano K, Kesteloot H. Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med 1999; 28: 520-529.
197. Gillurn RF, Mussolina M, Madans JH. The relatinr between fish consumption, death from all causes, and incidence of coronary heart disease: the NHANES I. Epidemiologic Follow-up Study. J Clin Epidemiol 2000; 53: 237-244.
198. Whelton SP, He J, Whelton PK, Muntner P. Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 2004; 93: 1119-1123.
199. Das UN. Prostacyclin as an endogenous anti-arrhythmic agent. Basic Res Cardiol 1983; 78: 716-718.
200. Das UN. Cardiac pacemaking, cardiac glycosides; anti-arrhythmic, drugs and prostaglandins. Speculations Sci Tech 1979; 2: 381-384.
201. Das UN. Prostaglandins and cardiac arrhythmias. Med J Australia 1981; 2: 157.
202. 2+ exchange in isolated myocardial muscle cells. Prostaglandins Leukot Med 1983; 12: 305-314.
203. Harris WS, Assaad B, Poston WC. Tissue omega-6ómega-3 fatty acid ratio and risk for coronary artery disease. Am J Cardiol 2006; 98 (suppl): 19i-26i.
204. Mozaffarian D, Ascherio A, Hu FB, Stampfer MJ, Willett WC, Siscovick DS, Rimm EB. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 2005; 111: 166-173.
205. Wood DA, Riemersma RA, Butler S, et al. Linoleic and eicosapentaenoic acids in adipose tissue and platelets and risk of coronary heart disease. Lancet 1987; i: 177-183.
206. Wood DA, Butler S, Riemersma RA, et al. Adipose tissue and platelet fatty acids and coronary heart disease in Scottish men. Lancet 1984; ii: 117-121.
207. Roberts TL, Wood DA, Riemersma RA, Gallagher PJ, Lampe FC. Linoleic acid and risk of sudden cardiac death. Dr Heart J 1993; 70: 524-529.
208. Luostarinen R, Boberg M, Saldeen T. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. Atherosclerosis 1993; 99: 187-193.
209. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-1345.
210. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised tontrolled trial. Lancet 2003; 361: 477-485.
211. Mozaffarian D. Trans fatty acids - effects on systemic inflammation and endothelial function. Atheroscler Suppl 2006; 7: 29-32.
212. Mozaffarian D, Rimm EB, King IB, Lawler BL, McDonald GB, Levy WC. Trans fatty acids and systemic inflammation in heart failure. Am J Clin Nutr 2004; 80: 1521-1525.
213. Willett WC, Stampfer MJ, Manson JE, et al. Intake of trans fatty acids and risk of coronary heart disease among women. Lancet 1993; 341: 581-585.
214. Ascherio A, Hennekens CH, Buring JE, Master C, Stampfer MJ, Willett WC. Trans-fatty acids intake and risk of myocardial infarction. Circulation 1994; 89: 94-101.
215. Juan H, Sametz W. Dihomo-gamma-linolenic acid increases the metabolism of eicosapentaenoic acid in perfused vascular tissue. Prostaglandins Leukotrienes Med 1985; 19: 79-86.
216. Das UN. Minerals, trace elements, and vitamins interact with essential fatty acids and prostaglandins to prevent hypertension, thrombosis, hypercho-lesterolemia, and atherosclerosis and their attendant complications. Med Sci Res 1985; 13: 684-687.
217. Bordet JC, Guichardant M, Lagarde M. Hydroperoxides produced by n-6 lipoxygenation of arachidonic and linoleic acids potentiate synthesis of prostacyclin related compounds. Biochim Biophys Acta 1988; 958: 460-468.
218. 3) production from eicosapentaenoic acid in human endothelial cells. Biochem Biophys Res Commun 1986; 135: 403-410.
219. Das UN. Oestrogen, statins and essential fatty acids: Similarity in their actions and benefits-is there a common link? Nutrition 2002; 18: 178-188.
220. Levine L. Statins stimulate arachidonic acid release and prostaglandin 12 production in rat liver cells. Lipids Health Dis 2003; 2: 1.
221. Jula A, Marniemi J, Ronnemaa T, Virtanen A, Huupponen R. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler Thromb Vasc Biol 2005; 25: 1952-1959.
222. Harris JI, Hibbeln JR, Mackey RH, Muldoon MF. Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients. Prostaglandins Leukot Essent Fatty Acids 2004; 71: 263-269.
223. Bellini MJ, Polo MP, de Alaniz MJ, de Bravo MG. Effect of simvastatin on the uptake and metabolic conversion of palmitic, dihomo-gamma-linoleic and alpha-linolenic acids in A549 cells. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 351-367.
224. Rise P, Pazzucconi F, Sirtori CR, Galli C. Statins enhance arachidonic acid synthesis in hypercholesterolemic patients. Nutr Metab Cardiovasc Dis 2001; 11: 88-94.
225. 4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929-935.
226. Morris T, Stables M, Gilroy DW. New perspectives on aspirin and the endogenous control of acute inflammatory resolution. Scientific World J 2006; 6: 1048-1065.
227. Schwab JM, Serhan CN. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 2006; 6: 414-420.
228. Serban CN. Novel omega - 3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 2005; 105: 7-21.
229. Mozaffarian D, Pischon T, Hankinson SE, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr 2004; 79: 606-612.
230. Baer DJ, Judd JT, Clevidence BA, Tracy RP. Dietary fatty acids affect plasma markers of inflammation in healthy men fed controlled diets: a randomized crossover study. Am J Clin Nutr 2004; 79: 969-973.
231. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 2005; 135: 562-566.
232. Lopez-Garcia E, Schultze MB, Manson JE, et al. Consumption of (n-3) fatty acids is related to plasma biomarkers of inflammation and endothelial activation in women. J Nutr 2004; 134: 1806-1811.
233. Kumar GS, Das UN, Kumar KV, Madhavi, Das NP, Tan BKH. Effect of n-6 and n-3 fatty acids on the proliferation and secretion of TNF and IL-2 by human lymphocytes in vitro. Nutrition Res 1992; 12: 815-823.
234. Kumar GS, Das UN. Effect of prostaglandins and their precursors on the proliferation of human lymphocytes and their secretion of tumor necrosis factor and various interleukins. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 331-334.
235. Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 1989; 30: 785-807.
236. Sanders TAB, Hinds A, Pereira CC. Influence of n-3 fatty acids on blood lipids in normal subjects. J Intern Med 1989; 225 (suppl 1): 99-104.
237. Putadechakum S Tanphaichitr V, Leelahagul P, Pakpeankitvana. V, Surapisitchart T, Komindr S. Long-term treatment of N-3 PUFAS on plasma lipoprotein levbls and fatty acid composition of total serum and erythrocyte lipids in hypertriglyceridemic patients. J Med Assoc Thai 2005; 88: 181-186.
238. Roche HMI Gibney MJ. Effect of long-chain n-3 polyunsaturated fatty acids on fasting-and postprandial triacylglycerol metabolism. Am J Clin Nutr 2000; 71(1 Suppl): 232S-237S.
239. Wilkinson P, Leach C, Ah-Sing N, et al. Influence of alphalinolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005; 181: 115-124.
240. Laidlaw M, Holub BJ. Effects of supplementation with fish oil-derived n-3 fatty acids and gamma-linolenic acid on circulating plasma lipids and fatty acid profiles in women. Am J Clin Nutr 2003; 77: 37-42.
241. GISSI Prevenzione Investigators. Dietary supplementation wid n-3 polyunsaturated fatty acids an vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999; 354: 447-455.
242. Davidson MH, Mechanisms for the hypertriglyceridewic effect of marine omega-3 fatty acids. Am J Cardiol 2006; 98(suppl): 27i:33i.
243. Leaf A, Weber PC. Cardiovascular effects of n-3 fatty acids. N Engl J Med 1988; 322: 697-698.
244. Dyerberg J, Bang HO. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 1979; ii: 433-435.
245. Pischer S, Weber PC, Dyerberg J. The prostacyclinthromboxane balance is favourably shifted in Greenland Eskimos, Prostaglandins 1986; 32: 235-241.
246. Kristensen SD, Schmidt EB, Dyerberg J. Dietary supplementation with n-3 polyun-saturated fatty acids and human platelet function: a review with particular emphasis on implications for cardiovascular disease. J Intern Med 1989; 225(suppl): 141-150.
247. Scheurlen M, Kirchner M, Clemens MR, Jaschonek K. Fish oil preparations rich in docosahexaenoic acid modify platelet responsiveness to prostaglandin-endoperoxidethromboxane A2 receptor agonists. Biochem Pharmacol 1993; 46:245-249.
248. Lefevre M, Kris-Etherton PM, Zhao G, Tracy RP. Dietary fatty acids, hemostasis, and cardiovascular disease risk. J Am Diet Assoc 4004; 104: 410-419.
249. Tholstrup T, Miller GJ, Bysted A, Sandstrom B. Effect of individual dietary fatty acids on postprandial activationof blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clih Nutr 2003; 77: 1125-1132.
250. Junker R, Pieke B, Schulte H, et al. Changes in hemostasis during treatment of hypertilglyceridemia with a diet rich in monounsaturated and n-3 polyunsaturated fatty acids in comparison with a low-fat diet. Thromb Res 2001; 101: 355-366.
251. Prichard BNC, Smith CCT, Ling KLE, Betteridge DJ. Fish oils and cardiovascular disease. BMJ 1995; 310: 819-820.
252. Ambring A, Juhansson M, Axelsen M, Gan L, Strandvik B, Friberg P. Mediterranean-inspired diet lowers the ratio of serum phospholipid n-6 to n-3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects: Am J Clin Nutr 2006; 83: 575-581.
253. De Caterina R, Massaro M. Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. J Membr Biol 2005; 206:103-116.
254. Chen, W, Esselman WJ, Jump DB, Busik JV. Anti-inflammatory effect of docosahexaenoic acid on cytokine-induced adhesion molecule expression in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci 2005; 46: 4342-4347.
255. Weber C, Erl W, Pietsch A, Danesch, U, Weber PC. Docosahexaenoic acid selectively attenuates induction of vascular cell adhesion molecule-1 and subsequent monocytic cell adhesion to human endothelial cells stimulated by tumor necrosis factor-alpha. Arterioscler Thromb Vasc Biol 1995; 15: 621-08.
256. Eschen O, Christensen JH, De Caterina R, Schmidt EB. Soluble adhesion molecules in healthy subjects: a dose-response study using n-3 fatty acids. Nutr Metab Cardiovasc Dis 2004; 14: 180-185.
257. Johansen O, Seljeflot I, Hostmark AT, Arnesen H. The effect of supplementation with omega-3 fatty acids on soluble markers of endothelial function in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1681-1686.
258. Morisaki N, Sprecher H, Milo GE, Cornwell DG. Fatty acid specificity in the inhibition of cell proliferation and its relationship to lipid peroxidation and prostaglandin biosynthesis. Lipids 1982; 17: 893-899.
259. Cornwell DG, Panganamala RV. Atherosclerosis: an intracellular defficiency in essential fatty acids. Prog Lipid Res 1981; 20: 365-376.
260. Hirafuji M, Machida T, Hamaue N, Minami M. Cardiovascular protective effects of n-3 polyunsaturated fatty acids with special emphasis on docosahexaenoic acid. J Pharmacol Sci 2003; 92: 308-316.
261. Abeyawardena M,YHead RJ. Long chain n-3 polyunsaturated fatty acids and blood vessel function. Cardiovasc Res 2001; 52: 361-371.
262. Pakala R, Pakala R, Sheng WL, Benedict CR. Eicosapentaenoic acid and docosahexaenoic acid block serotopin-induced smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol 1999; 19: 2316-2322.
263. Nakayama M, Fukuda N, Watanabe Y et al. Low dose of eicosapentaenoic acid inhibits exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypertens 1999; 17: 1421-1430.
264. Nobukata H, Ishikawa, T, Obata, M, Shibutani Y Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves the dysfunction of vascular endothelial and smooth muscle cells in male WBNKob rats. Metabolism 2000; 49: 1588-1591.
265. Mori, YNobukata H,. Harada T, Kasahara T, Tajima N. Long-term administration of highly purified eicosapentaenoic acid ethyl ester improves blood coagulation abnormalities and dysfunction of vascular endothelial cells in Otsuka Long-Evans Tokushima fatty rats. Endocr J 2003; 50: 603-611.
266. Huttner JJ, Gwebu ET, Panganamala RV, et al. Fatty acids and their prostaglandin derivatives: inhibitors of proliferation in aortic smooth muscle cells. Science 1977; 197: 289-291.
267. Fan, Y Ramos KS, Chapkin RS. Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice. J Nutr 2001; 131: 1675-16781.
268. Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol 1999; 33: 1619-1626.
269. Goodnight SH, Cairns JA, Fisher M, Fitzerald GA. Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. Chest 1992; 102: 374S-394S.
270. Israel DH, Gorlin R. Fish oils in the prevention of atherosclerosis. J Am Coll Cardiol 1992; 19: 174-185.
271. Komori K, Ishii T, Odashiro T, et al. Eicosapentaenoic acid reduces the intinial thickening of autogenous vein grafts and enhances endothelium-derived relaxing factor. J Surg Res 1995; 59: 747-753.
272. Boulanger C, Schini VB, Hendrickson H, Vanhoutte PM. Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 1990; 99: 176-180.
273. Lynn MA, Rupnow HL, Kleinhenz DJ, Kanner WA, Dudley SC, Hart CM. Fatty acids differentially modulate insulin-stimulated endothelial nitric oxide production by an Akt-independent pathway. J Investig Med 2004; 52: 129-136.
274. Fleischhauser FJ, W-D, Fishell TA. Fish oil improves endothelium-dependent coronary vasodilatation in heart transplant recipients. J Am Coll Cardiol 1993; 21: 982-989.
275. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka, Y Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 1999; 33: 633-640.
276. Omura M, Kobayashi S, Mizukami, Y et al. Eicosapentaenoic acid (EPA) induces Ca(2)-independent activation and translocation of endothelial nitric oxide synthase and endothelium-dependent vasorelaxation. FEBS Lett 2001; 487: 361-366.
277. Engler MB, Engler MM, Browne A, Sun Y, Sievers R. Mechanisms of vasorelaxation induced by eicosapentaenoic acid (20:5n-3) in WKY at aorta. Br J Pharmacol 2000; 131: 1793-1799.
278. Nishimura M, Nanbu A, Komori T, Ohtsuka K, Takahashi H, Yshimura M. Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats. Clin Exp Pharmacol Physiol 2000; 27: 618-624.
279. Prisco D, Paniccia R, Bandinelli B, et al. Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 1998; 91: 105-112.
280. Das UN. Long-chain polyunsaturated fatty Acids interact with nitric oxide, superoxide anion, and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 2004; 58: 195-203.
281. Das, UN. Nutritional factors in the pathobiology of human essential hypertension. Nutrition 200l; l7: 337-346.
282. Engler MM, Engler MB, Goodfriend TL, et al. Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Proc Soc Exp Biol Med 1999; 221:32-38.
283. Engler MM, Schambelan M, Engler MB, Ball DL, Goodfriend TL. Effects of dietary gamma-linolenic acid on blood pressure and adrenal angiotensin receptors in hypertensive rats. Proc Soc Exp Biol Med 1998; 218: 234-237.
284. Kumar KV, Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med 1997; 214: 374-379.
285. Kumar KV, Das UN, Naidu SK. Effect of cis-unsaturated fatty acids on cell membrane bound enzymes in vitro. Nutr Res 1992, 12: 549-560.
286. Ghafoorunnisa, Ibrahim A, Rajkumar L, Acharya V. Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats. J Nutr 2005; 135: 2634-2639.
287. Baur LA, O'Connor J, Pan DA, Storlien LH. Relationships between maternal risk of insulin resistance and the childs muscle membrane fatty acid composition. Diabetes 1999; 48: 12-116.
288. Das UN. Pathobiology of metabolic syndrome Xn obese and non-obese South Asian Indians: Further discussion and some suggestions. Nutrition 2003; 19: 560-562.
289. Das UN. The lipids that matter from infant nutrition to insulin resistance. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 1-12.
290. Das UN. Insulin resistance and hyperinsulinemia: are they secondary to an alteration in the metabolism of essential fatty acids? Med Sci Res 1994; 22: 243-245.
291. Das UN. GLUT-4, tumor necrosis factor, essential fatty acids and def-genes and their role in insulin resistance and non-insulin, dependent diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 13-20.
292. Ginsberg BH, Jabour J, Spector AA. Effect of alterations in membrane lipid unsaturation on the properties of the insulin receptor of Ehrlich ascites cells. Biochim Biophys Acta 1982; 690: 157-164.
293. Bruneau C, Staedel-Flaig C, Cremel G, Leray C, Beck JP, Hubert P. Influence of lipid environment on insulin binding in cultured hepatoma cells. Biochim Biophys Acta. 1987; 928: 287-296.
294. Cain BS, Harken AH, Meldrum DR. Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and perfusion. J Mol Cell Cardiol 1999; 31: 931-947.
295. Li D, Zhao L, Liu M, et al. Kinetics of tumor necrosis factor alpha in plasma and the cardioprotective effect of a monoclonal antibody to tumor necrosis factor alpha in acute myocardial infarction. Am Heart J 1999; 137: 1145-1152.
296. Kempf K, Haltern G, Futh R, et al. Increased TNF-alpha and decreased TGF-beta expression in peripheral blood leukocytes after acute myocardial infarction. Horm Metab Res 2006; 38: 346-351.
297. Pasqui AL, Di Renzo M, Bova G, et al. Pro-inflammatory anti-inflammatory cytokine imbalance in acute coronary syndromes. Clin Exp Med 2006; 6: 38-44.
298. Blancke F, Claeys MJ, Jorens P, et al. Systemic inflammation and reperfusion injury in patients with acute myocardial infarction. Mediators Inflamm 2005; 2005: 385-389.
299. Kosmala W, Przewlocka-Kosmala M, Mazurek W. Proinflammatory cytokines and myocardial viability in patients after acute myocardial infarction. Int J Cardiol 2005; 101: 449-456.
300. Irwin MW, Mak S, Mann DL, et al. Tissue expression and immunolocali-zation of tumor necrosis factor-alpha in post-infarction dysfunctional myocardium. Circulation 1999; 99: 1492-1498.
301. Das UN. Can free radicals cause acute myocardial infarction? Med Hypotheses 1992; 39: 90-94.
302. Gorog DA, Ahmed N, Davies GJ. Elevated plasma lipid peroxide levels in angina pectoris and myocardial infarction. Cardiovasc Pathol 2002; 11: 153-157.
303. Akiyama K, Kimura A, Suzuki H, et al. Production of oxidative products of nitric oxide in infarcted human heart. J Am Coll Cardiol 1998; 32: 373-379.
304. Sharber J. Oxygen radicals and calcium ion flux: role in reperfusion injury following AMI. Dimens Crit Care Nurs 1994; 13: 256-262.
305. Newman WH, Zunzunegui RG, Warejcka DJ, Dalton ML, Castiresana MR. A reactive oxygen-generating system activates nuclear factor-kappaB and releases tumor necrosis factor-alpha in coronary smooth muscle cells. J Surg Res 1999; 85: 142-147.
306. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in congestive heart failure. N Engl J Med 1990; 323: 236-241.
307. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J 1999; 20: 683-693.
308. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in cachectic" patients with severe chronic heart failure. Br Heart J 1991; 66: 356-358.
309. Cain BS, Harken AH, Meldrum SR. Therapeutic strategies to reduce TNF-alpha mediated cardiac contractile depression following ischemia and perfusion. J Mol Cell Cardiol 1999; 31: 951-947.
310. Cicoira M, Bolger AP, Doehner W, et al. High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 2001; 15: 80-86.
311. Fujita H, Morita I, Murota S. A specific involvement of ion transporters in tumor necrosis factor alpha and cycloheximide-induced apoptosis of endothelial cells. Mediators Inflamm 1999; 8: 211-218.
312. Meldrom DR, Donnahoo KK. Role of TNF in mediating renal insufficiency following cardiac surgery: evidence of a post bypass cardiorenal syndrome. J Surg Res 1999; 85: 185-199.
313. Ferrai R. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovasc Res 1998; 37: 554-559.
314. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989; 320: 265-271.
315. Purasiri P, Murray A, Richardson S, Heys SD, Horrobin DF, Eremin O. Modulation of cytokine production in vivo by dietary essential fatty acids in patients with colorectal cancer. Clin Sci 1994; 87: 711-717.
316. Meydani SN, Endres S, Woods MM, et al. Oral (n-3) fatty acid supplemen-tation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 1991; 121: 547-555.
317. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. J Heart Lung Transplant 2006; 25: 834-838.
318. Das UN. Beneficial effect of eicosapentaenoic and docosahexaenoic acids in the management of systemic lupus erythematosus and its relationship to the cytokine network. Prostaglandins Leukot Essent Fatty Acids 1994; 51: 207-213.
319. Guidot DM, Hybertson BM, Kitlowski RP, Repine JE. Inhaled nitric oxide prevents IL-1 induced neutrophil accumulation and associated acute edema in isolated rat lungs. Am J Physiol 1996; 271: L225-L229.
320. Arita M, Yoshida M, Hong S, et al. Resolvin El, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005; 102: 7671-7676.
321. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nature Med 2000; 6: 164-170.
322. Y CM, Lai KW, Chen XHuang K, Lan HYExpression of macrophage migration inhibitory factor in acute ischemic myocardial injury. J Histochem Cytochem 2003; 51: 625-631.
323. Takahashi M, Nishihira J, Shimpo M, et al. Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovasc Res 2001; 52: 438-445.
324. Marchiali R, Levantesi G, Macchia A, et al. GLSSI-Prevenzione Investigators, Antiarrhythmic mechanisms of n-3 PUFA and the results of the GISSI-Prevenzione trial. J Membr Biol 2005; 206: 117-128.
325. Leaf A, Albert CM, Josephson M, et al. Fatty Acid-Antiarrhythmia Trial, Investigators. Prevention of fatal, arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005; 111: 2762-2768.
326. Macchia A, Levantesi G, Frazosi MG, et al. GISSI-Prevenzione Investigators. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polysaturated fatfy acids. Eur J Heart Fail 2005; 7: 904-909.
327. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomised controlled trial. JAMA 2005; 293: 2884-2891.
328. Minami M, Kimura S, Endo T, el al. Dietary docosahexaenoic-acid inceases cerebral acetylcholine levels and improves passive avoidance performance in stroke-prone spontaneously hypertensive rats. Pharmacol Biochem Behav 1997; 58: 112; 1123-1129.
329. Watkins LR, Maier SF. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci USA 1999; 96: 7710-7713.
330. Sterrnberg EM. Neural-immune interactions in health and disease. J Clin Invest 1997; 100: 2641-2647.
331. Brorovicova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
332. Borovikova LV, Ivanova S, Nardi D, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci 2000; 95: 141-147.
333. Bernik TR, Friedman SG, Ochani M, et al. Pharmacological stimulation of the cholinergic antiinflammatory pathway. J Exp Med 2002; 195: 781-788.
334. WangH, Y M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
335. Das UN. Alcohol consumption and risk of dementia. Lancet 2002; 360: 490.
336. Smith JK, Dykes R, Douglas JE, Krishnaswamy G, Berk S. Longterm exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. JAMA 1999; 281: 1722-1727.
337. Lefer AM, Isao P, Aoki N, Palladino Jr. Mediation of cardioprotection by transforming growth factor-beta. Science 1990; 249:61-64.
338. Das UN, Transforming growth factor-beta: Is it an endogenous cardioprotector? Med Sci Res 1993; 21: 373-375.
339. Newman MJ. Inhibition of carcinoma and melanoma cell growth by type 1 transforming growth factor beta is dependent on the presence of polyunsaturated fatty acids. Proc Natl Acad Sci USA 1990; 87: 5543-5547.
340. Helge JW, Ayre KJ; Hulbert AJ,. Kiens B, Storlien LH. Regular exercise modulates muscle membrane phospholipid prefile in rats. J Nutr 1999; 129: 1636-1642.
341. Helge JW, Wu BJ, Willer M, Daugaard JR, Storlien LH, Kiens B. Training affects muscle phospholipid fatty acid composition in humans. J Appl Physiol 2001; 90: 670-677.
342. Das UN. Anti-inflammatory nature of exercise. Nutrition 2004; 20: 323-326.
343. Das UN Exercise and inflammation. Eur Heart J 2006; 27: 1385-1386.
344. Thompson PD, Cullinane EM, Sady SP, et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation 1988; 78: 25-34.
345. Rauramaa R, Salonen JT, Kukkonen-Harjula. K, et al. Effects of mild physical exercise on serum lipoproteins and metabolites of arachidonic acid: a controlled randomised trial in middle aged men. BMJ 1984; 288: 603-606.
346. Y GH, Zwas D, Wang J. Chronic exercise training preserves prostaglandin-induced dilation of epicardial coronary artery during development of heart failure in awake dogs. Prostaglandins Other Lipid Mediat 2000; 60: 137-151.
347. Laughlin MH, Rubin LJ, Rush JW, Price EM, Schrage WG, Woodman CR. Short-term training enhances. endothelium-dependent dilation of coronary arteries, not arterioles. J Appl Physiol 2003; 94: 234-244.
348. Traverse JR, Wang Y, Du R, et al. Coronary nitric oxide production in response to exercise and endothelium-dependent agonists. Circulation 2000; 101: 2526-2531.
349. Levy WC, Cerqueira MD, Harp GD, et al. Effect of endurance exercise training on heart rate variability at rest in healthy young and older men. Am J Cardiol 1998; 82: 1236-1241.
350. Stein PK, Ehsani AA, Domitrovich PP, Kleiger RE, Rottman JN. Effect of exercise training on heart rate variability in healthy older adults. Am Heart J 1999; 138(3 Pt 1): 567-576.
351. Das UN. Possible beneficial action(s) of glucose-insulin-potassium regimen in acute myocardial infarction and inflammatory conditions: a hypothesis. Diabetologia 2000; 43: 1081-1082.
352. Das UN. Is insulin an anti-inflammatory molecule? Nutrition 2001; 17: 409-413.
353. Das UN. Is insulin an endogenous cardioprotector? Crit Care 2002; 6: 389-393.
354. Podzuweit T, Lubbe WF, Opie LH. Cyclic adenosine monophosphate, ventricular fibrillation and anti-arrhythmic drugs. Lancet 1976; 1: 341-342.
355. Courtney KR, Colwell WT, Jensen RA. Prostaglandins and pacemaker activity in isolated guinea pig SA node. Prostaglandins 1978; 16:451-459.
356. Das UN. Cardiac pacemaking, cardiac glycosides, anti-arrhythmic drugs and prostaglandins. Speculations Sci Tech 1979; 2: 381-384.
357. Das UN. Cardiac arrhythmias, anti-arrhythmic drugs and prostaglandins. J Ind Med Assoc 1980; 74: 23-24.
358. 2+ exchange in isolated myocardial muscle cells. Prostaglandins Leukot Med 1983; 12: 305-314.
359. Das UN. Prostacyclin as an endogenous anti-arrhythmic agent. Basic Res Cardiol 1983; 78: 716-718.
360. Charnock JS, McLennan PL, Abeyawardena MY Dietary modulation of lipid metabolism and mechanical performance of the heart. Mol Cell Biochem 1992; 116: 19-25.
361. McMillin JB, Bick RJ, Benedict CR. Influence of dietary fish oil on mitochondrial function and response to ischemia. Am J Physiol 1992; 263(5 Pt 2): H1479-485.
362. Demaison L, Sergiet JP, Moreau D, Grynberg A. Influence of the phospholipid n-6n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. Biochim Biophys Acts, 1994; 1227: 53-59.
363. Kang JXLeaf A. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci USA 1994; 91: 9886-9890.
364. Kang JXLeaf A. Protective effects of free polyunsaturated fatty acids on arrhythmias induced by lysophosphatidylcholine or palmitoylcarnitine in neonatal rat cardiac myocytes. Eur J Pharmacol. 1996; 297: 97-106.
365. + channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1995; 92: 11000-11004.
366. Xo,Y Li X Polyunsaturated fatty acids modify mouse hipopcampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 1999; 846: 112-121.
367. Xo Y, Ke Q, Chen, Y Morgan JP, Leaf A. Inhibitory effect of n-3 fish oil fatty acids on cardiac NaCa2+exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004; 321: 116-123.
368. Das UN. Is angiotensin II an endogenous pro-inflammatory molecule? Med Sci Monit 2005; 11: RA155-RA162.
369. Kumar KV, Das UN. Effect of cis-unsaturated fiaty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med 1997; 214: 374-379.
370. Okuda, Y Kawashima K, Sawada T, et al. Eicosapentaenoic acid enhances nitric oxide production by cultured human endothelial cells. Biochem Biophys Res Commun, 4997; 232: 487-491.
371. Bunk S. ACEs wild. Scientist 2002; 16(24): 22-24.
372. Moskowitz DW. Is angiotensin I-converting enzyme a master' disease gene? Diabetes Tech Therapeut 2002; 4: 683-711.
373. Gilroy DW. New insights into the anti-inflammatory actions of aspirin- induction of nitric oxide through the generation of epilipoxins. Mem Inst Oswaldo Cruz 2005; 100(Suppl 1): 49-54.
374. Wang W, Diamond SL. Boes. elevated nitric oxide production enhance the release of prostacyclin from shear stressed aortic endothelial cells? Biochem Biophys Res Commun 1997; 233: 748-751.
375. El-Sohemy A, Archer MC. Regulation of mevalonate syntesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids. Lipids 1929; 34: 1037-1043.
376. Das UN. Essential fatty acids and osteoporosis. Nutrition 2000; I6: 286-290.
377. Nakamura N, Hamazaki T, Jokaji N, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid cconcentration in patients with hyperlipidemia. Int J Clin Lab Res 1998; 28: 192-195.
378. Artandi SE. Telomeres, telomearse, and humah disease. N Engl J Med 2006; 355: 1195--1197.
379. Brouilette SW, Moore JS, McMahon AD, et al. for the West of Scotland Coronary Prevention Study Gmup. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study, Lancet 2007; 369: 107-114.
380. Obana. N, Takagi S, Kinouchi, Y et al. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern Med 2003; 42: 150-153.
381. Nakashima H, Ozono R, Suyama C, Sueda T, kambe M, Oshima T. Telomere attrition in white blood cell correlating with cardiovascular damage. Hypertens. Res 2004; 27: 319:325.
382. Jeanclos E, Krolewski A, Skurnick J, et al. Shortened telomere length in white blood cells of patienis with IDDM. Diabetes 1998; 47: 482-486.
383. Sampson MJ, Winterborne MS, Hughes JC, Dozio N, Hughes DA. Monocyte telomere-shortening and oxidative DNA damage in type 2 diabetes. Diabetes Care 2006; 29: 283-289.
384. Benetos A, Gardner JP, Zureik M, et al. Short telomeres are associated with increased carotid atherosclerosis in hypertensive subjects. Hypertension 1004; 43: 182-185.
385. Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham Heart Study. Aging Cell 2006; 5: 325-330.
386. Gardner JP, Li S, Srinivasan SR, et al. Rise inmsulin resistance is associated with escalated telomere attrition. Circulation 2005; 111: 2171-2177.
387. Vasa M, Breitschopf K, Zeiher AM, Dimmeler S. Nitric oxide activates telomerase and delays endothelial cell senescence. Circ Res 2000; 87: 540-542.
388. Hayashi T, Matsui-Hirai H, Miyazaki-Akita A, et al. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci USA 2006; 103: 17018-17023.
389. Scalera F, Borlak J, Beckmann B, et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl L-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol 2004; 24: 1816-1822.
390. Bode Roger SM, Scalera F, Martens-Lobenhoffer J. Asymmetric dimethylar-ginine (ADMA) accelerates cell senescence. Vasc Med 2005; 10 (Suppl. 1): S65-S71.
391. Minamino T, Miyauchi H, Yshida T, Ishida, Y Yshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105. 1541-1544.
392. Matsushita H, Chang E, Glassford AJ, Cooke JP, Chiu CP, Sao PS. eNOS activity is reduced in senescent human endothelial cells: Preservation by hTERT immortalization. Circ Res 2001; 89: 793-798.
393. Eitsuka T, Nakagawa K, Suzuki T, Miyazawa T. Polyunsaturated fatty acids inhibit telomerase activity in DLD-1 human colorectal adenocarcinoma cells: a dual mechanism approach. Biochim Biophys Acta 2005; 1737: 1-10.
394. Eitsuka T, Nakagawa K, Miyazawa T. Dual mechanisms for telomerase inhibition in DLD-1 human colorectat adenocarcinoma cells by polyun-saturated fatty acids. Biofactors 2004; 21: 19-21.
395. 4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidine-diones. Circulation 2006; 114: 873-875.
396. Lea EJ, Jones SP, Hamilton DV. The fatty acids of erythrocytes of myocardial infarction patients. Atherosclerosis 1982; 41: 363-369.
397. Lemaitre RN, King IB, Raghunathan TE, et al. Cell membrane trans-fatty acids and the risk of primary cardiac arrest. Circulation 2002; 105: 697-701.
398. Miettinen TA, Naukkarinen V, Huttunen JK, Mattila S, Kumlin T. Fatty acid composition of serum lipids predicts myocardial, infarction. BMJ 1982; 285: 993-996.
399. Simon JA, Hodgkins ML, Browner WS, Neuhaus JK Bernert JT Jr, Hulley SB. Serum fatty acids and the risk of coronary heart disease. Am J Epidemiol 1995; 142: 469-476.
400. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of longchain n-3 fatty acids an4 the risk of sudden death. N Engl J Med 2002; 346: 1113-1118.
401. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid (EPA) on major coronary events in hypercholesterolemic patients (JELIS): a randomized open-label blinded endpoint analysis, Lancet 2007; 369: 1090-1098.